Royal Bank of Canada
EIDX

Royal Bank of Canada’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Royal Bank of Canada’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-48
Closed -$6K – 7948
2020
Q4 		$6K Buy
+48
New +$4.24K ﹤0.01% 6614
2020
Q2 		– Sell
-49
Closed -$2K – 7108
2020
Q1 		$2K Sell
49
-87
-64% -$4.43K ﹤0.01% 6375
2019
Q4 		$7K Buy
136
+85
+167% +$4.21K ﹤0.01% 6275
2019
Q3 		$2K Hold
51
– – ﹤0.01% 6351
2019
Q2 		$2K Hold
51
– – ﹤0.01% 6640
2019
Q1 		$1K Sell
51
-195
-79% -$3.13K ﹤0.01% 6718
2018
Q4 		$4K Sell
246
-83
-25% -$1.05K ﹤0.01% 6281
2018
Q3 		$3K Buy
+329
New +$5.41K ﹤0.01% 6468

Royal Bank of Canada's EIDX Position: Q1 2021 in Review

Royal Bank of Canada sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 48 shares — an estimated $6K sold.

Royal Bank of Canada first reported a position in EIDX in Q3 2018 and held it in 8 quarters. The position peaked at $7K in Q4 2019. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Royal Bank of Canada reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Royal Bank of Canada sold 48 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $6K.
  • Royal Bank of Canada first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 8 quarters.
  • Royal Bank of Canada's Eidos Therapeutics, Inc. Common Stock position peaked at $7K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Royal Bank of Canada's 13F filing for Q1 2021, filed 17 May 2021.